NASDAQ:SPHS - Sophiris Bio Stock Price, Forecast & News

Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."

Sophiris Bio Inc (NASDAQ:SPHS) announced its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.02. View Sophiris Bio's Earnings History.

Sophiris Bio is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Sophiris Bio.

3 analysts have issued 12-month price targets for Sophiris Bio's stock. Their forecasts range from $2.80 to $6.00. On average, they anticipate Sophiris Bio's share price to reach $4.60 in the next year. This suggests a possible upside of 538.9% from the stock's current price. View Analyst Price Targets for Sophiris Bio.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sophiris Bio.

News coverage about SPHS stock has been trending very negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sophiris Bio earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Sophiris Bio.

Some companies that are related to Sophiris Bio include Trevi Therapeutics (TRVI), Chimerix (CMRX), Otonomy (OTIC), Proteostasis Therapeutics (PTI), Axovant Gene Therapies (AXGT), Sunesis Pharmaceuticals (SNSS), Enlivex Therapeutics (ENLV), TFF Pharmaceuticals (TFFP), Synlogic (SYBX), Vaccinex (VCNX), Immunic (IMUX), VERONA PHARMA P/S (VRNA), Sesen Bio (SESN), Oramed Pharmaceuticals (ORMP) and CV Sciences (CVSI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sophiris Bio investors own include Sarepta Therapeutics (SRPT), Intercept Pharmaceuticals (ICPT), Celator Pharmaceuticals (CPXX), SLS International (SLS), Heat Biologics (HTBX), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), Verastem (VSTM), Novavax (NVAX) and Rigel Pharmaceuticals (RIGL).

Sophiris Bio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.66%) and Wedbush Securities Inc. (0.26%). View Institutional Ownership Trends for Sophiris Bio.

SPHS stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Wedbush Securities Inc.. View Insider Buying and Selling for Sophiris Bio.

Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SPHS stock can currently be purchased for approximately $0.72.

Sophiris Bio has a market capitalization of $24.82 million. The biopharmaceutical company earns $-6,780,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe.View Additional Information About Sophiris Bio.

The official website for Sophiris Bio is http://www.sophirisbio.com/.

Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]